---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Heterogeneity of treatment effect"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Heterogeneity of treatment effect. Topics: HPV status: response at 1500 mg weekly in the phase 1b cohort, HPV status: progression-free and overall survival at 1500 mg weekly, HPV status at an earlier data cut of the same cohort, HPV-positive tumors by smoking history, and 9 further topics. 13 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### HPV status: response at 1500 mg weekly in the phase 1b cohort

> “In the HPV-negative subgroup (n = 28), the confirmed ORR was 54% (n = 15; 95% CI, 34 to 73), including six patients (21%) with CR”
> “In the HPV-positive subgroup (n = 11), the confirmed ORR was 27% (n = 3; 95% CI, 6 to 61), including two patients (18%) with CR; the CBR was 55% (n = 6; 95% CI, 23 to 83).”
> “Median time to response was 1.4 months (95% CI, 1.4 to 4.7) in the HPV-negative subgroup and 4.1 months (95% CI, 1.3 to 12.0) in the HPV-positive subgroup.”
> “Notably, the ORR and CBR were higher in the HPV-negative versus HPV-positive subgroup.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.3-2"></a>

### HPV status: progression-free and overall survival at 1500 mg weekly

> “In the HPV-negative and HPV-positive subgroups, median (95% CI) PFS was 9.9 (4.4 to 22.7) and 2.0 (1.0 to 10.0) months, and 12-month PFS rates (95% CI) were 48.0% (28.9 to 67.1) and 20.8% (0 to 46.3), respectively”
> “Median OS (95% CI) in these subgroups was 21.3 (9.9 to NE) and 16.4 (2.6 to 25.7) months, respectively”
> “subsequent OS assessment in April 2025 showed 24-month OS rates in the HPV-negative and HPV-positive subgroups of 46% (95% CI, 23 to 65) and 27% (95% CI, 1.0 to 53.6), respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.3-3"></a>

### HPV status at an earlier data cut of the same cohort

> “Among the EE pts, the ORR was 54% (21/39; 95% CI: 37–70) in the overall cohort and 64% (18/28; 95% CI: 44–81) in HPV-negative pts.”

Source: [Chung et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.6017)

<a id="topic-2.2.2.3-4"></a>

### HPV-positive tumors by smoking history

> “In HPV-positive patients classified as smokers (>10 pack-year smoking history; n = 4) or nonsmokers (n = 7), ORR was 75% and 0%, and CBR was 100% and 29%, respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.3-5"></a>

### PD-L1 CPS 1-19 versus 20 or greater at 1500 mg weekly

> “Of patients in the HPV-negative subgroup who had a CPS of 1-19 (n = 13) or ≥20 (n = 15), confirmed ORRs were 54% (95% CI, 25 to 81) and 53% (95% CI, 27 to 79), respectively; three additional patients with CPS ≥20 had an unconfirmed response.”
> “In subgroups with CPS 1-19 (n = 19) or ≥20 (n = 20), median (95% CI) PFS was 7.4 (2.7 to NE) and 13.4 (2.8 to 23.2) months, and median OS was 22.0 (7.4 to NE) and 20.6 (6.8 to NE) months, respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.3-6"></a>

### Locoregional recurrence, tumor burden, and performance status at 1500 mg weekly

> “Within the HPV-negative subgroup, responses occurred in 15 of 21 patients (71%) with locoregionally recurrent disease (with or without distant metastases) and 7 of 14 patients (50%) with baseline sum of target lesions >50 mm.”
> “In patients with ECOG PS 0 (n = 15) or 1 (n = 24), median PFS was 6.9 (2.7 to NE) and 13.4 (4.2 to 26.4) months, and median OS was 20.6 (7.7 to NE) and 26.4 (6.8 to NE) months, respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.2.3-7"></a>

### Confirmed response by CPS, tumor burden, and disease extent across the three dose cohorts

| Subgroup, % (n/N) | 750 mg weekly (n=30) | 1500 mg weekly (n=28) | 2000 mg every 2 weeks (n=27) |
| --- | --- | --- | --- |
| CPS 1-19 | “73 (8/11)” | “54 (7/13)” | “57 (8/14)” |
| CPS 20 or greater | “47 (9/19)” | “53 (8/15)” | “38 (5/13)” |
| Sum of target lesion diameters 50 mm or less | “55 (11/20)” | “53 (8/15)” | “53 (9/17)” |
| Sum of target lesion diameters greater than 50 mm | “60 (6/10)” | “54 (7/13)” | “40 (4/10)” |
| Sum of target lesion diameters greater than 70 mm | “50 (2/4)” | “43 (3/7)” | “33 (2/6)” |
| Locoregional disease only | “38 (6/16)” | “62 (5/8)” | “50 (7/14)” |
| Distant metastatic disease only | “100 (5/5)” | “29 (2/7)” | “40 (2/5)” |
| Locoregional and distant metastatic disease | “67 (6/9)” | “62 (8/13)” | “50 (4/8)” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-2.2.2.3-8"></a>

### Dose cohort: response depth and progression-free survival

| Dose cohort | Confirmed ORR (95% CI) | Complete response | Responders with deep response | Median PFS (95% CI), months |
| --- | --- | --- | --- | --- |
| 750 mg weekly | “57% (37%-74%)” | “13%” | “47% (8/17)” | “6.9 (4.6-NE)” |
| 1500 mg weekly | “54% (34%-72%)” | “25%” | “80% (12/15)” | “9.9 (4.4-22.7)” |
| 2000 mg every 2 weeks | “48% (29%-68%)” | “30%” | “77% (10/13)” | “12.7 (4.9-NE)” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “ORRs were comparable across all three evaluated dose levels and responses occurred rapidly, with higher dose intensities driving maximal tumor shrinkage”
> “A clear dose-response relationship was observed; escalation from 750 mg (median PFS 6.9 months) to the 1500 mg (median PFS 9.9 months) and 2000 mg Q2W (median PFS 12.7 months) cohorts illustrates the clinical value of optimized TGF-β neutralization and sustained disease control across varying doses and schedules”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-2.2.2.3-9"></a>

### Dose cohort: 1500 mg versus 750 mg weekly at the December 2025 data cut

> “Improved outcomes were observed in the 1500 mg vs 750 mg cohort, including deep responses (≥80% tumor shrinkage in 80% vs 47% of responders) and mPFS (9.9 mo vs 6.9 mo), along with increased markers of TGF-β inhibition and tumor penetration in paired biopsies, and increased pro-inflammatory cytokines in blood (Table).”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

<a id="topic-2.2.2.3-10"></a>

### Pembrolizumab monotherapy in KEYNOTE-048 by PD-L1 CPS

> “The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994”
> “The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.3-11"></a>

### Pembrolizumab in KEYNOTE-048: CPS 1-19 and CPS less than 1 subgroups

> “For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 subgroup (hazard ratio [HR], 1.51 [95% CI, 0.96 to 2.37]) and 10.8 versus 10.1 months in the CPS 1-19 subgroup (HR, 0.86 [95% CI, 0.66 to 1.12]).”
> “Increased efficacy of pembrolizumab or pembrolizumab-chemotherapy was observed with increasing PD-L1 expression.”

Source: [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)

<a id="topic-2.2.2.3-12"></a>

### Pembrolizumab in KEYNOTE-048: other subgroups and HPV status

> “In subgroup analyses, HRs generally favored pembrolizumab alone except for recurrent-only disease (locally recurrent disease and disease that spread to cervical lymph nodes”
> “including in patients with poor prognostic markers such as smoking history and HPV-negative oropharyngeal cancer.”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

> “HPV status according to p16 IHC (positive or negative)”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.3-13"></a>

### Real-world first-line pembrolizumab by HPV status and primary site

> “Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors; 17 months for those with an ECOG PS of 0–1 versus 6 months for those with an ECOG PS of 2–4; and 13 months for those with oropharyngeal tumors versus 9 months for those with tumors of the larynx, 5 months for those with oral cavity tumors, and 6 months for individuals with tumors of the hypopharynx”
> “Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

Additional sources: [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/); [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
